Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4947412 | 0.89 | KMT2A (0.57) | KMT2AEPHX2LTA4H | |
| SCHEMBL14759878 | 0.87 | KMT2A (0.60) | KMT2AEPHX2FABP5FABP7 | |
| SCHEMBL307643 | 0.86 | KMT2A (0.57) | KMT2AEPHX2FABP5FABP7ALDH1A1 | |
| SCHEMBL16476528 | 0.84 | KMT2A (0.51) | KMT2AEPHX2FABP5FABP7 | |
| SCHEMBL4951870 | 0.83 | KMT2A (0.51) | KMT2AEPHX2 | |
| SCHEMBL3623157 | 0.82 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7 | |
| SCHEMBL5148061 | 0.81 | KMT2A (0.70) | KMT2AEPHX2FABP5FABP7ALDH1A1 | |
| SCHEMBL5972005 | 0.81 | KMT2A (0.70) | KMT2AEPHX2FABP5FABP7HDAC3 | |
| SCHEMBL2401694 | 0.81 | KMT2A (0.70) | KMT2AEPHX2FABP5FABP7HDAC3 | |
| SCHEMBL10261416 | 0.81 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859506-B2 | Glycopeptide phosphonate derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140024604-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8541375-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120283195-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8101575-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110257364-A1 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7858583-B2 | Process for purifying glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100160211-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700550-B2 | Telavancin or its hydrochloride salt for infection, including MRSA infections; reduced tissue accumulation and/or nephrotoxicity | THERAVANCE, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090215673-A1 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | CUMBERLAND PHARMACEUTICALS INC. | 2009-08-27 | — | — | US | disclosed |
| US-20050164916-A1 | highly effective antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals | CUMBERLAND PHARMACEUTICALS INC. | 2005-07-28 | — | — | US | disclosed |
| US-6887976-B2 | Improved mammalian safety profile; glycopeptide phosphonate derivatives of invention unexpectedly exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammal; antibacterial agents | THERAVANCE, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6872701-B2 | Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful | THERAVANCE, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1487863-A2 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPOHONATE DERIVATIVES | Theravance, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040063916-A1 | Bactericides; antibiotics | CUMBERLAND PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030207797-A1 | Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful | CUMBERLAND PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6635618-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030119722-A1 | Process for purifying glycopeptide phosphonate derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003018608-A2 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024604-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | KMT2A 4796/4885EPHX2 4691/4885FABP5 2120/4885 |
| US-20090215673-A1 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PGLS, GYPA, PAG1 | KMT2A 4074/4885EPHX2 4167/4885FABP5 2347/4885 |
| US-20100160211-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | KMT2A 4796/4885EPHX2 4691/4885FABP5 2120/4885 |
| US-20030119722-A1 | Process for purifying glycopeptide phosphonate derivatives | PGLS, GYPA, PAG1 | KMT2A 4074/4885EPHX2 4167/4885FABP5 2347/4885 |
| US-20120283195-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | KMT2A 4796/4885EPHX2 4691/4885FABP5 2120/4885 |
| US-20110257364-A1 | PROCESS FOR PURIFYING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PGLS, GYPA, PAG1 | KMT2A 4074/4885EPHX2 4167/4885FABP5 2347/4885 |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | GLS, PIGS, PAG1 | KMT2A 4773/4885EPHX2 4555/4885FABP5 1107/4885 |
| US-20050164916-A1 | highly effective antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals | GLS, PAG1, FUT6 | KMT2A 4765/4885EPHX2 4469/4885FABP5 1940/4885 |
| US-20030207797-A1 | Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful | PAG1, PTMS, B3GAT3 | KMT2A 4794/4885EPHX2 4175/4885FABP5 2221/4885 |
| US-20040063916-A1 | Bactericides; antibiotics | PGLS, PAG1, BPGM | KMT2A 4885/4885EPHX2 4464/4885FABP5 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.